RESOURCES

Blogs

Insight at the intersection of data science and real-world health

The Talking Room

Demystifying AI, LLMs and machine learning

Use Cases

How teams put the signals to work

Compliance Hub

Data integrity, ethical AI and regulatory standards

DrugVoice

Built to be defensible.

Compliance, ethics, and data integrity are part of the process.

TMLABS

About us

Where our proprietary models are trained, tested and refined

Articles & scientific publications

Peer-reviewed methodologies and validated outcomes

Latest paper

The New GLP-1 Consumer

Articles & Scientific Publications

DRUGVOICE

DrugVoice

Measure how your messaging lands and evidence what moved

SEE IT IN ACTION

Bring us a question you can’t answer.

We’ll show you what the conversation already contains, using your therapy area and your audience.

ABOUT US

About us

Where our proprietary models are trained, tested and refined

ESG

Responsible innovation and ethical data practice

WHO WE ARE

Data scientists who speak pharma.

A team built around one problem: making real-world conversation usable at scale.

Talking Medicines identified as top AI Company

Data tech innovator Talking Medicines, which uses advanced AI to provide pharmaceutical companies with real-time data intelligence, has been chosen to join Tech Nation’s Applied AI 2.0 Growth Programme. Tech Nation’s growth programmes are designed to champion and support ‘the UK’s most exceptional deep tech scaleups’ and alumni include Skyscanner, Darktrace, and Monzo. The programme forms part of the UK Government’s AI Sector Deal, supported by the Office for AI.

Glasgow and London-based Talking Medicines was selected to join the programme after a competitive and rigorous judging process. The programme supports companies, according to Tech Nation, to ‘scale up and become the AI unicorns of the future’.

Formed in 2013 to create new ways of capturing the digital voice of the patient, Talking Medicines uses a collection of tech tools to capture and analyse the conversations and behaviours of patients at home.Through mapping the patient voice to regulated medicine information, the company is able to build data points to deliver trends and patterns of usage across medicines and brands driven by the health consumer. This intelligence enables marketing in big pharma to score patient confidence in their medicines. Real-time, compliant insights can replace traditional focus groups, prescriber reports and clinical profiles to tell pharmaceutical companies who is using their medicines, how, and what they really think of their brands.

Dr Elizabeth Fairley, COO, Talking Medicines, said: “Our aim is to help people take the right medicines that have the best chance of working for them. Pharmaceutical companies are becoming more aware of the need to measure the performance of drugs and identify strategies for improvement post launch. Our systems use AI to cleanse and structure information from millions of conversations and direct patient-use data.

“Being selected for the Tech Nation’s Applied AI 2.0 Growth Programme has happened at just the right time for us to take our scalable data intelligence product to the next level. Through this programme we are keen to push our boundaries, connect with the very best in AI and learn as much as we can.”

Sign Up to Stay Ahead of Message Impact

Discover how Pharma marketeers are finally measuring which messages change HCP behavior. Our newsletter shares evidence-led insights powered by DrugVoice and the Message Resonance Score™ so you can predict and prove message impact—before prescriptions are written.

Subscribe on LinkedIn

Read More

#
$